{"transactions":[{"id":1134741,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":79311,"kind":"person","name":"Colabuono Peter","position":1,"cik":"0001819620","reported_name":"Colabuono Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-23T17:50:43.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing on the grant date of May 21, 2025, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date."}],"balance_after":20000,"derivative":{"exercise_price":0.39,"expiration_date":"2035-05-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-25-014400","document":"form4-05232025_050539.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746466/000141588925014400/form4-05232025_050539.xml","form_type":"4"}},{"id":1333414,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":79311,"kind":"person","name":"Colabuono Peter","position":1,"cik":"0001819620","reported_name":"Colabuono Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-12-12T22:45:27.000Z","date":"2024-12-11","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 36 equal monthly installments following the grant date of December 11, 2024."}],"balance_after":40000,"derivative":{"exercise_price":0.7,"expiration_date":"2034-12-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-029164","document":"form4-12122024_101224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746466/000141588924029164/form4-12122024_101224.xml","form_type":"4"}},{"id":2250847,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":79311,"kind":"person","name":"Colabuono Peter","position":1,"cik":"0001819620","reported_name":"Colabuono Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T10:08:17.000Z","date":"2022-05-31","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":10.95,"expiration_date":"2030-11-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-020086","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1651431/000089924322020086/doc4.xml","form_type":"4"}},{"id":2250846,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":79311,"kind":"person","name":"Colabuono Peter","position":1,"cik":"0001819620","reported_name":"Colabuono Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T10:08:17.000Z","date":"2022-05-31","kind":"disposition_to_issuer","acquired":false,"shares":10030,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":6.27,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":10030},"source":{"system":"sec-edgar","filing":"0000899243-22-020086","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651431/000089924322020086/doc4.xml","form_type":"4"}},{"id":2659924,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":79311,"kind":"person","name":"Colabuono Peter","position":1,"cik":"0001819620","reported_name":"Colabuono Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T21:18:28.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":10030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 16, 2021 with respect to 10,030 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date."}],"balance_after":10030,"derivative":{"exercise_price":6.27,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":10030},"source":{"system":"sec-edgar","filing":"0000899243-21-025173","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651431/000089924321025173/doc4.xml","form_type":"4"}},{"id":2982537,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":79311,"kind":"person","name":"Colabuono Peter","position":1,"cik":"0001819620","reported_name":"Colabuono Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-12T17:13:38.000Z","date":"2020-11-10","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33.3% of the shares subject to such option vest and become exercisable on August 6, 2021 and the remainder of the shares vest in substantially equal monthly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":20000,"derivative":{"exercise_price":10.95,"expiration_date":"2030-11-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-20-030841","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1651431/000089924320030841/doc4.xml","form_type":"4"}}]}